India may extend duty exemptions on pharma inputs beyond June 30
The Indian government is considering extending duty exemptions on critical petrochemical inputs for the pharmaceutical sector beyond June 30. These measures aim to stabilize supply chains and support India's goal of reaching $50 billion in pharma exports by 2030.
Why it matters
Maintaining these exemptions is crucial for India's competitive edge in the global generic drug market and overall manufacturing stability.
India is reviewing the months-old duty-related relief measures for pharma sector amid the evolving situation in West Asia and likely to extend the exemptions beyond June 30, a senior official in the Centre’s Department of Commerce said here on Tuesday.
The article provides a factual report on government policy and industry goals.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in